-
1
المساهمون: Uludağ Üniversitesi/Tıp Fakültesi/Dermatoloji Anabilim Dalı., Turan, Hakan, Başkan, Emel Bülbül, Tunalı, Şükran, Yazıcı, Serkan, Sarıcaoğlu, Hayriye, AAH-1388-2021, AAH-2459-2021
مصطلحات موضوعية: Adult, Male, medicine.medical_specialty, Clinical article, MEDLINE, Drug response, Dermatology, Skin manifestation, Article, medicine, Humans, Treatment outcome, Middle aged, Drug safety, Fatigue, Priority journal, business.industry, Retrospective cohort study, Nausea, Retrospective studies, Drug efficacy, Methotrexate, Clinical feature, Drug dose reduction, Female, Lichen Planus, Vincent Stomatitis, Pemphigus, business, Lichen planus, Dermatologic agents, medicine.drug, Human
URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d977bfde6b747278053c117cb61c974a
http://hdl.handle.net/11452/23002 -
2
المؤلفون: Steven Paul Nistico, Sergio Chimenti, Marina Papoutsaki, Annamaria Mazzotta, Antonio Costanzo
مصطلحات موضوعية: rheumatoid arthritis, Male, drug safety, psoriasis vulgaris, corticosteroid, cyclosporin, etanercept, methotrexate, retinoid, tumor necrosis factor, adult, body surface, clinical article, clinical trial, controlled clinical trial, controlled study, disease activity, disease severity, drug efficacy, drug tolerability, female, follow up, human, injection site, letter, male, open study, priority journal, side effect, skin manifestation, treatment outcome, urticaria, aged, clinical assessment, drug tolerance, drug withdrawal, laboratory test, monotherapy, psoriasis area and severity index, psoriatic arthritis, rating scale, Adult, Aged, Anti-Inflammatory Agents, Non-Steroidal, Female, Humans, Immunoglobulin G, Middle Aged, Psoriasis, Receptors, Tumor Necrosis Factor, Severity of Illness Index, Treatment Outcome, Tumor Necrosis Factor-alpha, Anti-Inflammatory Agents, Etanercept, Receptors, Medicine, Plaque psoriasis, Settore MED/35 - Malattie Cutanee e Veneree, Non-Steroidal, Efficacy Study, medicine.drug, medicine.medical_specialty, Dermatology, In patient, business.industry, business, Tumor Necrosis Factor
URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dff580022ef87f5e1c4622905522e95f
http://hdl.handle.net/2108/33747 -
3
المؤلفون: Fábio Vieira Teixeira, Rafael Denadai, Ricardo Romiti, Rogerio Saad-Hossne, Flavio Steinwurz
المساهمون: Universidade Estadual Paulista (Unesp), Hospital Israelita Albert Einstein, Universidade de São Paulo (USP)
المصدر: Scopus
Repositório Institucional da UNESP
Universidade Estadual Paulista (UNESP)
instacron:UNESPمصطلحات موضوعية: Exacerbation, Inflammatory bowel disease, tumor necrosis factor alpha inhibitor, Etanercept, Adalimumab, chemistry.chemical_compound, systematic review, adalimumab, Biological therapy, enteritis, Infliximab, Crohn's disease, azathioprine, Gastroenterology, Antibodies, Monoclonal, Crohn disease, General Medicine, psoriasis, Psoriasis, spondylarthritis, priority journal, mesalazine, drug withdrawal, medicine.drug, medicine.medical_specialty, corticosteroid, review, Certolizumab, methotrexate, pustulosis palmoplantaris, skin manifestation, Mesalazine, Gastrointestinal Agents, medicine, Humans, human, business.industry, medicine.disease, Inflammatory Bowel Diseases, Dermatology, Surgery, certolizumab pegol, chemistry, business, infliximab, etanercept
URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::00948a5d557a079fcea82c2af986db1c